CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 471 filers reported holding CRISPR THERAPEUTICS AG in Q3 2021. The put-call ratio across all filers is 1.71 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $333,000 | +22.4% | 5,101 | +14.2% | 0.01% | +27.3% |
| Q2 2022 | $272,000 | +15.7% | 4,468 | 0.0% | 0.01% | +22.2% |
| Q1 2022 | $235,000 | +9.8% | 4,468 | +57.9% | 0.01% | +28.6% |
| Q4 2021 | $214,000 | -97.3% | 2,830 | -95.9% | 0.01% | -97.7% |
| Q3 2021 | $7,790,000 | +1847.5% | 69,597 | +2715.4% | 0.31% | +1812.5% |
| Q2 2021 | $400,000 | +63.9% | 2,472 | +23.6% | 0.02% | +45.5% |
| Q1 2021 | $244,000 | -20.3% | 2,000 | 0.0% | 0.01% | -21.4% |
| Q4 2020 | $306,000 | – | 2,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |